Vera Therapeutics, Inc.(VERA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VERA Vera Therapeutics, Inc.

Trading 03-26 11:04:15 EDT

39.94

-0.22

-0.55%

High40.52	Low39.26	Vol73.31K
Open39.46	D1 Closing40.16	Amplitude3.14%
Mkt Cap2.85B	Tradable Cap2.00B	Total Shares71.36M
T/O2.93M	T/O Rate0.15%	Tradable Shares50.20M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VERA","market":"US","secType":"STK","nameCN":"Vera Therapeutics, Inc.","latestPrice":39.94,"timestamp":1774537454945,"preClose":40.16,"halted":0,"volume":73306,"delay":0,"changeRate":-0.005478087649402363,"floatShares":50198200,"shares":71355667,"eps":-4.664443,"marketStatus":"Trading","change":-0.22,"latestTime":"03-26 11:04:15 EDT","open":39.46,"high":40.52,"low":39.26,"amount":2929428.494982,"amplitude":0.031375,"askPrice":40.17,"askSize":22,"bidPrice":39.71,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-4.664443,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1774555200000},"marketStatusCode":2,"adr":0,"listingDate":1620964800000,"exchange":"NASDAQ","adjPreClose":40.16,"preHourTrading":{"tag":"盘前","latestPrice":39.65,"preClose":40.16,"latestTime":"09:07 EDT","volume":4509,"amount":180202.306743,"timestamp":1774530477634,"change":-0.51,"changeRate":-0.012699,"amplitude":0.049303},"postHourTrading":{"tag":"盘后","latestPrice":40.16,"preClose":40.16,"latestTime":"19:57 EDT","volume":25357,"amount":1018346.34,"timestamp":1774483030350,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.159921,"impliedVol":0.8032,"impliedVolPercentile":0.4741},"requestUrl":"/m/hq/s/VERA/wiki","defaultTab":"wiki","newsList":[{"id":"2622078867","title":"Vera Therapeutics appoints Jane Wright-Mitchell chief legal officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2622078867","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622078867?lang=en_us&edition=fundamental","pubTime":"2026-03-25 19:30","pubTimestamp":1774438229,"startTime":"0","endTime":"0","summary":"Vera Therapeutics appointed Jane Wright-Mitchell as Chief Legal Officer, effective immediately.Wright-Mitchell previously served as a fractional general counsel supporting public and private life sciences companies.Her prior roles include General Counsel, Chief Compliance Officer and Corporate Secretary at Vaxcyte, and Chief Legal Officer positions at other pharmaceutical and research companies.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL5FDKSy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","BK4139","IE00BGHQF748.EUR","LU2095319765.USD","SG9999014005.SGD","SG9999014021.USD","LU0053671581.USD","SG9999014039.USD","IE0009354923.USD","IE00BN0W2W23.USD","PCVX","NDAQ","SG9999014013.SGD","BK4112","IE00BKPKM429.USD","BK4539","IE00BN0W2T93.GBP","VERA","LU2210149790.SGD","BK4585","BK4588","LU2324357040.USD","LU0314104364.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2620342250","title":"Analysts Conflicted on These Healthcare Names: Cochlear (OtherCHEOF), Universal Health (UHS) and Vera Therapeutics (VERA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620342250","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620342250?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:30","pubTimestamp":1773750629,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cochlear (CHEOF – Research Report), Universal Heal...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-cochlear-othercheof-universal-health-uhs-and-vera-therapeutics-vera-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-cochlear-othercheof-universal-health-uhs-and-vera-therapeutics-vera-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","BK4585","BK4588","UHS","BK4137","BK4185","LU0029874061.USD","LU0128526141.USD","XLV","XBI","VERA","HCSG","LABU","BK4139","LU2324357040.USD","BK4539"],"gpt_icon":0},{"id":"2619464244","title":"Assessing Vera Therapeutics (VERA) Valuation As Deerfield Ups Stake And FDA Priority Review Nears","url":"https://stock-news.laohu8.com/highlight/detail?id=2619464244","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619464244?lang=en_us&edition=fundamental","pubTime":"2026-03-16 21:10","pubTimestamp":1773666627,"startTime":"0","endTime":"0","summary":"Vera Therapeutics (VERA) is back on investors’ radar after Deerfield Management Company added 418,538 shares in the fourth quarter, as the market watches an FDA priority review decision for lead drug candidate atacicept.\nSee our latest analysis for Vera Therapeutics.\nAt a share price of $39.96, Vera’s recent 7 day share price return of 2.54% sits against a 30 day share price return decline of 5.35% and a 90 day share price return decline of 17.27%. The 1 year total shareholder return of...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/assessing-vera-therapeutics-vera-valuation-as-deerfield-ups","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/assessing-vera-therapeutics-vera-valuation-as-deerfield-ups","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4539","VERA","LABU","BK4585","BK4588","DCF","LU2324357040.USD","BK4139"],"gpt_icon":0},{"id":"2618944664","title":"Vera Therapeutics Raised to Outperform From Peer Perform by Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2618944664","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618944664?lang=en_us&edition=fundamental","pubTime":"2026-03-11 19:55","pubTimestamp":1773230100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VERA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 11, 2026 07:55 ET (11:55 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERA"],"gpt_icon":0},{"id":"2618967707","title":"Vera Therapeutics upgraded to Outperform from Peer Perform at Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2618967707","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618967707?lang=en_us&edition=fundamental","pubTime":"2026-03-11 07:05","pubTimestamp":1773183913,"startTime":"0","endTime":"0","summary":"Wolfe Research analyst Andy Chen upgraded Vera Therapeutics (VERA) to Outperform from Peer Perform with an $88 price target. Vertex’s (VRTX) report...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-upgraded-to-outperform-from-peer-perform-at-wolfe-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-upgraded-to-outperform-from-peer-perform-at-wolfe-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VERA"],"gpt_icon":0},{"id":"2618778496","title":"Vera Therapeutics appoints Christopher Hite to board","url":"https://stock-news.laohu8.com/highlight/detail?id=2618778496","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618778496?lang=en_us&edition=fundamental","pubTime":"2026-03-10 05:02","pubTimestamp":1773090156,"startTime":"0","endTime":"0","summary":"Vera Therapeutics appointed Christopher Hite to its board, effective immediately. Hite will serve as a Class III director with a term expiring at the 2027 annual meeting of stockholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 09, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nNDLcbQvVM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","VERA","BK4539","BK4139","LU2324357040.USD"],"gpt_icon":0},{"id":"2617702630","title":"Vera Therapeutics Grants Inducement Stock Options and RSUs to Six New Hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2617702630","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617702630?lang=en_us&edition=fundamental","pubTime":"2026-03-07 05:05","pubTimestamp":1772831115,"startTime":"0","endTime":"0","summary":"Vera Therapeutics granted inducement awards to six new employees under its 2024 Inducement Plan, consisting of non-qualified stock options for 46,000 Class A shares and RSUs covering 25,875 Class A shares. The options have an exercise price of $39.30 per share and vest over four years, with 25% vesting after one year and the remainder vesting monthly over the next 36 months. The RSUs also vest over four years, with 25% vesting on each anniversary of either February 20 or May 20, 2026, depending on the employee’s start date.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDLc275ZH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2210150020.SGD","SG9999014021.USD","SG9999014039.USD","BK4112","LU0314104364.USD","IE00BKPKM429.USD","VERA","IE00BGHQF748.EUR","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2095319765.USD","BK4588","BK4539","SG9999014005.SGD","NDAQ","LU2324357040.USD","BK4585","LU2210149790.SGD"],"gpt_icon":0},{"id":"2617658592","title":"Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2617658592","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617658592?lang=en_us&edition=fundamental","pubTime":"2026-03-07 05:05","pubTimestamp":1772831100,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., March  06, 2026  (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on March 3, 2026, the Compensation Committee of the Board of Directors (Compensation","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/06/3251308/0/en/Vera-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4539","VERA","LU2324357040.USD","BK4139"],"gpt_icon":0},{"id":"2617523074","title":"Vera Therapeutics appoints Hite to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2617523074","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617523074?lang=en_us&edition=fundamental","pubTime":"2026-03-05 22:16","pubTimestamp":1772720191,"startTime":"0","endTime":"0","summary":"Vera Therapeutics (VERA) announced the appointment of Christopher Hite to Vera Therapeutics’ Board of Directors. Published first on TheFly – the ul...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-appoints-hite-to-board-of-directors-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-appoints-hite-to-board-of-directors-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LU2324357040.USD","VERA","BK4588","BK4139","BK4585"],"gpt_icon":0},{"id":"2617523822","title":"Vera Therapeutics Appoints Christopher Hite to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2617523822","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617523822?lang=en_us&edition=fundamental","pubTime":"2026-03-05 22:00","pubTimestamp":1772719200,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., March  05, 2026  (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/05/3250276/0/en/Vera-Therapeutics-Appoints-Christopher-Hite-to-Board-of-Directors.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4539","BK4139","VERA","BK4585","LU2324357040.USD"],"gpt_icon":0},{"id":"2616332316","title":"Vera Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2616332316","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616332316?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:53","pubTimestamp":1772455980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VERA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 02, 2026 07:53 ET (12:53 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERA"],"gpt_icon":0},{"id":"2616770339","title":"Bank of America Securities Reaffirms Their Buy Rating on Vera Therapeutics (VERA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616770339","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616770339?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:57","pubTimestamp":1772452658,"startTime":"0","endTime":"0","summary":"In a report released today, Dina Ramadane from Bank of America Securities reiterated a Buy rating on Vera Therapeutics, with a price target of $66....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-reaffirms-their-buy-rating-on-vera-therapeutics-vera-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-reaffirms-their-buy-rating-on-vera-therapeutics-vera-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VERA","BAC"],"gpt_icon":0},{"id":"2616335065","title":"Vera Therapeutics price target raised to $110 from $90 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2616335065","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616335065?lang=en_us&edition=fundamental","pubTime":"2026-03-02 19:11","pubTimestamp":1772449901,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on Vera Therapeutics (VERA) to $110 from $90 and keeps a Buy rating on the shares. The firm updated ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-price-target-raised-to-110-from-90-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-price-target-raised-to-110-from-90-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VERA"],"gpt_icon":0},{"id":"2614816513","title":"Positive Phase 3 IgA Data and FDA Priority Review Could Be A Game Changer For Vera Therapeutics (VERA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614816513","media":"Simply Wall St.","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614816513?lang=en_us&edition=fundamental","pubTime":"2026-02-28 17:30","pubTimestamp":1772271010,"startTime":"0","endTime":"0","summary":"Vera Therapeutics reported full-year 2025 results showing a net loss of US$299.62 million, while advancing atacicept with positive Phase 3 IgA nephropathy data and securing FDA priority review with a July 7, 2026 PDUFA date.\nAlongside filing a US$191.89 million Class A common stock shelf registration for an ESOP-related offering, the company highlighted that its cash, equivalents, marketable securities and debt facility availability are expected to fund operations through potential atacicept...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/positive-phase-3-iga-data-and-fda-priority-review-could-be-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vera/vera-therapeutics/news/positive-phase-3-iga-data-and-fda-priority-review-could-be-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","BK4139","BK4585","VERA","BK4539"],"gpt_icon":0},{"id":"2614938448","title":"Vera Therapeutics: Strong Atacicept Phase 3 Data and Favorable Regulatory, Commercial Setup Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2614938448","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614938448?lang=en_us&edition=fundamental","pubTime":"2026-02-28 06:45","pubTimestamp":1772232326,"startTime":"0","endTime":"0","summary":"Ritu Baral, an analyst from TD Cowen, maintained the Buy rating on Vera Therapeutics. The associated price target remains the same with $73.00. Rit...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/vera-therapeutics-strong-atacicept-phase-3-data-and-favorable-regulatory-commercial-setup-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/vera-therapeutics-strong-atacicept-phase-3-data-and-favorable-regulatory-commercial-setup-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VERA"],"gpt_icon":0},{"id":"2614856514","title":"Wedbush Raises Price Target on Vera Therapeutics to $35 From $33, Keeps Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2614856514","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614856514?lang=en_us&edition=fundamental","pubTime":"2026-02-27 21:14","pubTimestamp":1772198066,"startTime":"0","endTime":"0","summary":"Vera Therapeutics (VERA) has an average rating of buy and mean price target of $77.23, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VERA"],"gpt_icon":0},{"id":"2614537448","title":"Guggenheim Keeps Their Buy Rating on Vera Therapeutics (VERA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614537448","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614537448?lang=en_us&edition=fundamental","pubTime":"2026-02-27 20:39","pubTimestamp":1772195955,"startTime":"0","endTime":"0","summary":"In a report released yesterday, from Guggenheim reiterated a Buy rating on Vera Therapeutics, with a price target of $56.00. The company’s shares c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-vera-therapeutics-vera-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-keeps-their-buy-rating-on-vera-therapeutics-vera-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VERA"],"gpt_icon":0},{"id":"2614775320","title":"Vera Therapeutics Q4 EPS $(1.39) Misses $(1.31) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2614775320","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614775320?lang=en_us&edition=fundamental","pubTime":"2026-02-27 06:49","pubTimestamp":1772146192,"startTime":"0","endTime":"0","summary":"Vera Therapeutics (NASDAQ:VERA) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(1.31) by 6.19 percent. This is a 93.06 percent decrease over losses of $(0.72) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50916305/vera-therapeutics-q4-eps-1-39-misses-1-31-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Vera Therapeutics Q4 EPS $(1.39) Misses $(1.31) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERA"],"gpt_icon":0},{"id":"2614007459","title":"Vera Therapeutics: Buy Rating Backed by Strong Atacicept Data, Robust Cash Runway, and Large IgAN Market Opportunity","url":"https://stock-news.laohu8.com/highlight/detail?id=2614007459","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614007459?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:56","pubTimestamp":1772142961,"startTime":"0","endTime":"0","summary":"Vera Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Rami Katkhuda from LifeSci Capital assigned...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/vera-therapeutics-buy-rating-backed-by-strong-atacicept-data-robust-cash-runway-and-large-igan-market-opportunity-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/vera-therapeutics-buy-rating-backed-by-strong-atacicept-data-robust-cash-runway-and-large-igan-market-opportunity-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VERA"],"gpt_icon":0},{"id":"2614007627","title":"Vera Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2614007627","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614007627?lang=en_us&edition=fundamental","pubTime":"2026-02-27 05:13","pubTimestamp":1772140421,"startTime":"0","endTime":"0","summary":"Vera Therapeutics Inc reports results for the quarter ended September 30 - Earnings SummaryVera Therapeutics Inc VERA.OQ reported a quarterly adjusted loss of $1.39 per share for the quarter ended Sep","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nL8N3ZM38D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERA","BK4139","BK4585","BK4588","BK4539"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.veratx.com","stockEarnings":[{"period":"1week","weight":0.048},{"period":"1month","weight":-0.0452},{"period":"3month","weight":-0.2786},{"period":"6month","weight":0.4241},{"period":"1year","weight":0.4902},{"period":"ytd","weight":-0.207}],"compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":-0.0375},{"period":"3month","weight":-0.0486},{"period":"6month","weight":-0.0076},{"period":"1year","weight":0.1414},{"period":"ytd","weight":-0.0368}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":0.057587},{"month":2,"riseRate":0.4,"avgChangeRate":0.015839},{"month":3,"riseRate":0.4,"avgChangeRate":-0.048108},{"month":4,"riseRate":0,"avgChangeRate":-0.100599},{"month":5,"riseRate":0.25,"avgChangeRate":-0.061241},{"month":6,"riseRate":0.4,"avgChangeRate":0.164504},{"month":7,"riseRate":0.8,"avgChangeRate":0.137629},{"month":8,"riseRate":0.6,"avgChangeRate":0.019112},{"month":9,"riseRate":0.6,"avgChangeRate":0.088867},{"month":10,"riseRate":0.2,"avgChangeRate":-0.071412},{"month":11,"riseRate":0.8,"avgChangeRate":0.292871},{"month":12,"riseRate":0.6,"avgChangeRate":0.07812}],"exchange":"NASDAQ","name":"Vera Therapeutics, Inc.","nameEN":"Vera Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vera Therapeutics, Inc.(VERA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vera Therapeutics, Inc.(VERA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vera Therapeutics, Inc.,VERA,Vera Therapeutics, Inc.股票,Vera Therapeutics, Inc.股票老虎,Vera Therapeutics, Inc.股票老虎国际,Vera Therapeutics, Inc.行情,Vera Therapeutics, Inc.股票行情,Vera Therapeutics, Inc.股价,Vera Therapeutics, Inc.股市,Vera Therapeutics, Inc.股票价格,Vera Therapeutics, Inc.股票交易,Vera Therapeutics, Inc.股票购买,Vera Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vera Therapeutics, Inc.(VERA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vera Therapeutics, Inc.(VERA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction